Treatment of Alzheimer's disease: Acetylcholinesterase enzyme inhibitors;Tratamiento de la enfermedad de Alzheimer: Farmacos inhibidores de la enzima acetilcolinesterasa

Neurologia

Volumn 14, Issue 4, 1999, Pages 180-188

  Lopez Pousa S ^a   Lombardia Fernandez C ^a  

^a HOSPITAL SANTA CATERINA   (Spain)

Author keywords

Alzheimer; Donepezil; Metriphonate; Rivastigmine; Treatment

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; METRIFONATE; RIVASTIGMINE;

ACETYLCHOLINE BRAIN LEVEL; ALZHEIMER DISEASE; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; PATHOPHYSIOLOGY; REVIEW;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS;

EID: 18844482214     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Geula C, Mesulam MM, Saroff DM, Wu CK. Relationship between plaques, tangles and loss of cortical cholinergic fibers in Alzheimer's disease. J Neuropathol Exp Neurol 1998; 57: 63-75.
2. Geula C, Mesulam MM. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. En: Terry RD, Katzman R, Bick KL, editores. Alzheimer disease. Nueva York: Raven Press, 1994: 263-291.
3. Lehericy S, Hirsch EC, Cervera-Piérot P, Hersch LB, Cakchine S, Piette F et al. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease. J Comp Neurol 1993; 330: 15-31.
4. German DC, White CL III, Sparkman DR. Alzheimer's disease: neurofibrillary tangles in nuclei that project to the cerebral cortex. Neuroscience 1987; 21: 305-312.
5. Geula C, Shatz CR, Mesulam MM. Differential localization of NADPH-Diaphprase and calbindin-D28k within the cholinergic neurons of the basal forebrain, striatum and brainstem in the rat, monkey, baboon and human. Neuroscience 1993; 54: 461-476.
6. Squire LR, Zola-Morgan S. The medial temporal lobe memory system. Science 1991; 253: 1.380-1.386.
7. Stoehr JD, Mobley SL, Roice D, Brooks R, Baker LM, Wiley RG et al. The effects of selective cholinergic basal forebrain lesions and aging upon expectancy in the rat. Neurobiol Learn Mem 1997; 67: 214-227.
8. Doraiswamy PM. Current cholinergic therapy for symptoms of Alzheimer's disease. Primary Psychiatry 1996; 3: 3-11.
9. Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase, inhibitor for Alzheimer disease. Alzheimer Dis Assoc Disord, 1996; 10: 124-131.
10. Koelle GB, editor. Cholinesterase and anticholinesterase agents. Handbook of experimental pharmacology. Vol. 15. Berlín: Springer-Verlag, 1963.
11. López-Pousa S, Serra-Mestres J. Tratamiento médico de la enfermedad de Alzheimer. Rev Neurol 1998; 26: 1.054-1.060.
12. Farlow MR, Evans RM. Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology 1998; 51 (Supl 1): S36-S44.
13. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
14. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1.356-1.364.
15. Cummings JL. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology 1997; 48 (Supl 6): S10-S16.
16. Adapted from food and drug administration department of health and human services. Correspondence, 16, November 1991.
17. Reisberg M, Ferris SH, CIBIC-plus interview guide. Nueva York: New York University, 1994.
18. Peripheral and central nervous system drugs advisory Commitee Meeting. July 7, 1989. Rockville MD: Department of Health and Human Services, Publi Health Service; Food and Drug Administration, 1989; 227.
19. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Brit J Psychiatry 1968; 114: 797-811.
20. DeJong R, Osterlund OW, Roy GW. Measurement of quality-of-life changes in patients with Alzheimer's disease. Clin Ther 1988; 139: 1.136-1.139.
21. Hughs CD, Berg L, Danziger L, Coben LA, Martin RL. A new rating scale for the staging of dementia. Br J Psychiatry 1982; 140: 566-572.
22. Gauthier L, Gauthier S, Gelina I, McIntyre M, Wood-Dauphinee S. Assessment of funtioning and ADL [resumen]. Proc Sixth Cong Psychogeriatr Assoc 1993;9.
23. Rogers SL, Yamanishi Y, Yamatsu K. E2020: the pharmacology of a piperidine cholinesterase inhibitor. En: Becker R, Giacobini E, editores. Cholinergic basis for Alzheimer therapy. Boston: Birkhäuser, 1991; 314-320.
24. Nochi S, Asakawa N, Sato T. Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-([5,6-dimethoxy-1 -indanon]-2-yl)methylpiperidine hydrochloride (E2020). Biol Pharm Bull 1995; 18: 1.145-.1.147.
25. Mihara M, Ohnishi A, Tomono Y. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 1993; 31: 223-229.
26. Yamanishi Y, Ogura H, Kosasa T. Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase in aged rats [resumen]. Eur J Pharmacol 1990; 183: 1.935.
27. Rogers SL, Walters EJ, Friedhoff LT. The pharmacokinetics (PK) and pharmacodynamics (PD) of E2020 ([R, S]-1-benzyl-4-[[5,6-dimethoxy-1-indanon]-2-yl]methylpiperidine hydrochloride), a novel inhibitor of acetylcholinesterase (Ache): implications for use in the treatment of Alzheimer's disease [resumen]. Neurobiol Aging 1992; 13: 496.
28. Ohnishi A, Mihara M, Kamakura H. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol 1993; 33: 1.086-1.091.
29. Tiseo PJ, Rogers SL, Friedhoff LT. The pharmacokinetics profile of donepezil HCL (E2020) in patients with imparied liver function. Clin Pharmacol Ther 1997; 61: 184.
30. Rogers SL, Tiseo PJ, Friedhoff LT. Pharmacokinetics of donepezil HCL (E2020) are unchanged in patients with imparied renal function. Clin Pharmacol Ther 1997; 61: 217.
31. Bryson HM, Benfield P. Donepezil. Drugs Aging 1997; 10: 234-239.
32. Rogers SL, Friedhoff LT, Donepezil study group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303.
33. Rogers SL, Perdomo C, Friedhoff LT. Clinical benefits are maintained during long-treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020 [resumen]. Neuropsychopharmacol 1995; 5: 386-387.
34. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, The Donepezil Study Group. A 24-week, double-bind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-145.
35. Tiseo PJ, Rogers SL, Friedhoff LT. Co-administration of donepezil HCl and digoxin produces no pharmacokinetics of pharmacodynamic interactions. Neuropsychopharmacol 1997; 7 (Supl 2): 4.024.
36. Tiseo PJ, Rogers SL, Friedhoff LT. The pharmacokinetics and pharmacodynamics of (R)-and (S)-warfarin are unaffected by co-administration of donepezil HCl. Eu Neuropsychopharmacol 1997; 7 (Supl 2): 4.023.
37. Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: an overview. J Drug Dev Clin Pract 1996; 8: 1-8.
38. Anand R, Gharabawi G. Clinical Development of Exelon (ENA-713): the ADENA programme. J Drug Dev Clin Pract 1996; 8: 9-14.
39. Kennedy JS, Polinsky RJ, Johnson B. Plasma and CSF pharmacokinetic/pharmacodynamic profiles of SDZ ENA-713 in man. Poster presented at American Collegium Neuropsychopharmacologium meeting. San Juan, Puerto Rico, 1995.
40. a ed.). New Jersey: Sandoz Research Institute, 1994.
41. Anand R, Gharabawi G. The ADENA programme: international coordinated phase III development of a second generation of acetylcholinesterase inhibitor (SDZ ENA-713). Poster presented at the Lancet Conference. Edimburgo: The Challenge of the Dementias. April 25-26, 1996.
42. Sandoz Alzheimer's drug "impressive". Scrip 1996; 2.132: 22.
43. Sramek JJ, Anand R, Wardle TS, Irwin P, Hartman RD, Cutler NR. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci 1996; 58: 1.201-1.207.
44. Promising results with Sandoz' Exelon in Alzheimer's. Scrip 1996; 2.512: 22.
45. Data on file. Summary of product characteristics. January 1998. Novartis Pharmaceuticals Corporation.
46. Data on file. Draft lavelling-April 1997, NDA 20-823. Novartis Pharmaceuticals Corporation.
47. Schmidt BH, Hinz V, Bloklan A, Van der Dtaay FJ, Fanelli RJ. Preclinical pharmacology of metrifonate: a promise for Alzheimer therapy. En: Becker R, Giacobini E and Robert P, editores. Alzheimer disease: from molecular biology to therapy. Boston: Birkhäuser, 1996; 217.
48. Aronson MK, Stella CD, German P. Psychiatric diagnosis and uncooperative behavior in nursing homes. J Geriatr Psychiatry Neurol 1992; 5: 102-105.
49. Hinz V, Grewing S, Schmidt BH. Metrifonate and dichlorvos: effects of a single oral administration on cholinesterase activity in rat brain and blood. Neurochem Res 1996; 21: 339-345.
50. Cummings J, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B. Metrifonate treatment of the cognitive deficits of Alzheimer's Disease. Neurology 1998; 50: 1.214-1.221.
51. Becker RE, Giacobini E, Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: clinical, pharmacological and therapeutic aspects. Drug Develop Res 1988; 12: 163-195.
52. Giacobini E. Modulation of brain acetylcoline levels with cholinesterase inhibitors as a treatment of Alzheimer disease. Keio J Med 1987; 36: 381-391.
53. Hallak M, Giacobini E. A comparison of the effects of two inhibitors on brain cholinesterase. Neuropharmacology 1987; 26: 521-530.
54. Becker RE, Colliver J, Elble R, Feldman E, Giacobini E, Kumar V et al. Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer disease: report of an open trial. Drug development research 1990; 19: 425-434.
55. Unni L, Womack R, Hannant ME, Becker RE. Pharmacokinetics and pharmacodynamics of metrifonate in humans. Meth Find Exp Clin Pharmacol 1994; 16: 285-289.
56. Bassant MH, Jazat-Poindessous F, Lamour Y. Effects of metrifonate, a cholinesterase inhibitor, on local cerebral glucose utilization in young and aged rats. J Cereb Blood Flow Metab 1996; 16: 1.014-1.025.
57. Lamb HM, Faulds D. Metrifonate. Adis New Drug profile 1997; 11: 490-497.
58. Pettigrew LC, Bieber F, Lettieri J, Wermeling D, Schmitt FA, Wekstein DR et al. Pharmacokinetics, pharmacodynamics and safety of metrifonate in patients with Alzheimer's disease. J Clin Pharmacol 1998; 38: 236-245.
59. Cummings J, Mas J, Orazem J, Gulanski B. Metrifonate in Alzheimer's disease: results of a dose-finding study. En: Iqbal K, Winblad B, Nishimura T, Takeda M. Wisniewski, editores. Alzheimer's disease: biology, diagnosis and therapeutics. John Wiley & Sons Ltd., 1997; 665-669.
60. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's Disease. Neurology 1998; 50: 1.222-1.1230.
61. Cummings J. Metrifonate: overview of safety and efficacy. Pharmacotherapy 1998; 18: 43-46.
62. Bieber F. Treatment effects of metrifonate in Alzheimer's disease [resumen]. Israel: OHOLO 1997; 2.
63. Feldmeier H, Doehring E. Clinical experience with metrifonate. Acta Tropica 1987; 44: 357-368.